# Intercell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intercell

- Industry: Pharmaceuticals
- Headquarters: Vienna, Austria
- Website: www.intercell.com
- Total disclosed funding: $81M
- Latest round: Series C (Nov 21, 2003)
- Investors on record: 11

## About

Intercell AG is based in Austria and engages in development, research and commercialization of novel vaccines and monoclonal antibodies for the prevention and treatment of infectious diseases.

## Funding rounds

- Series C, Nov 21, 2003, $16M — MPM BioImpact
- Series C, Jul 17, 2003, $34M — Apax Partners, STAR Ventures, Global Life Science Ventures, TVM Capital Life Science, Nomura Private Equity, NIBC Holding N.V.
- Series B, Jan 12, 2001, $25M — Apax Partners, AlpInvest Partners, TVM Capital Life Science, Go Equity Beteiligungsberatung, Nomura Asset Management, Sal. Oppenheim jr. & Cie.
- Series A, Jun 1, 1999, $5.5M — TVM Capital Life Science

## Investors

- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A, Series B, Series C
- Apax Partners (https://capitalatlas.ai/funds/apax-partners) — Series B, Series C
- AlpInvest Partners — Series B
- Go Equity Beteiligungsberatung (https://capitalatlas.ai/funds/go-equity-beteiligungsberatung) — Series B
- Nomura Asset Management (https://capitalatlas.ai/funds/nomura-asset-management) — Series B
- Sal. Oppenheim jr. & Cie. — Series B
- STAR Ventures — Series C
- Global Life Science Ventures (https://capitalatlas.ai/funds/global-life-science-ventures) — Series C
- Nomura Private Equity (https://capitalatlas.ai/funds/nomura-private-equity) — Series C
- NIBC Holding N.V. — Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series C